title: Febuxostat: a novel agent for management of hyperuricemia in gout.
abstract: Gout is a metabolic disorder characterized by elevated uric acid levels in the body, associated with painful arthritis, tophi and nephropathy. The most frequently used pharmacologic urate lowering strategies involve reducing urate production with a xanthine oxidase inhibitor and enhancing urinary excretion of uric acid with a uricosuric agent. Urate lowering agents are limited in number, availability and effectiveness. The emergence of a new medication, febuxostat, to lower serum urate levels is welcome as no new drug have been approved since the introduction of allopurinol, in 1964, and the drugs that are available have limitations owing to inefficacy or toxicity. Febuxostat is a novel, nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout.
authors.affiliation: Department of Pharmacology and E.N.T., Himalayan Institute of Medical Sciences, HIHT University, Jolly grant, Dehradun-248 140, India.
authors.forename: Manisha
authors.initials: M
authors.lastname: Bisht
authors.forename: S S
authors.initials: SS
authors.lastname: Bist
keywords: Gout; hyperuricemia; xanthine oxidase inhibitor